OneAscent Financial Services LLC Acquires 1,495 Shares of GSK plc (NYSE:GSK)

OneAscent Financial Services LLC boosted its stake in shares of GSK plc (NYSE:GSK) by 25.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,408 shares of the pharmaceutical company’s stock after acquiring an additional 1,495 shares during the quarter. OneAscent Financial Services LLC’s holdings in GSK were worth $251,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GSK. Indiana Trust & Investment Management Co increased its position in shares of GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 500 shares during the last quarter. Crews Bank & Trust purchased a new position in GSK during the fourth quarter worth $26,000. ST Germain D J Co. Inc. boosted its stake in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 522 shares during the period. Sunbelt Securities Inc. increased its position in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. Finally, Sierra Ocean LLC purchased a new stake in shares of GSK in the fourth quarter valued at $32,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Price Performance

Shares of GSK stock opened at $36.49 on Friday. The company has a market capitalization of $75.53 billion, a P/E ratio of 22.95, a P/E/G ratio of 1.12 and a beta of 0.56. The company’s 50-day simple moving average is $37.63 and its two-hundred day simple moving average is $36.59. GSK plc has a one year low of $31.72 and a one year high of $45.93. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, equities analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.31%. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 98.74%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley started coverage on GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.